Entero Therapeutics Stock Quote ENTO - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

0.63

Bid

0.581

Ask

0.698

Volume

64,938

0.5735 Day's Range 0.6615

0.185 52 Week Range 3.16

Previous Close

0.6184

Open

0.5998

Last Trade

0.5805

Last Trade Time

Average Volume (3m)

486,595

Financial Volume

$ 39,579

VWAP

0.609482

Form 8-K - Current report

Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum

BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company

Proposed merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing (i) Journey’s next-gen, first-in-class ADC-rivalling, nano-immunoconjugates (“NIC”) platform...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 4 - Statement of changes in beneficial ownership of securities

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), (“Entero Therapeutics” or the “Company”), a clinical-stage biopharmaceutical company specializing...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.0032	0.510529674537	0.6268	0.67	0.5214	93982	0.57363379	CS
4	0.21	50	0.42	0.926	0.39	334415	0.72076404	CS
12	0.271	75.4874651811	0.359	0.926	0.32	486595	0.61451446	CS
26	-1.28	-67.0157068063	1.91	2.29	0.185	521972	0.4877512	CS
52	-2.33	-78.7162162162	2.96	3.16	0.185	448570	0.50150789	CS
156	-2.33	-78.7162162162	2.96	3.16	0.185	448570	0.50150789	CS
260	-2.33	-78.7162162162	2.96	3.16	0.185	448570	0.50150789	CS

ENTO - Frequently Asked Questions (FAQ)

What is the current Entero Therapeutics share price?

The current share price of Entero Therapeutics is $ 0.63

What is the 1 year trading range for Entero Therapeutics share price?

Entero Therapeutics has traded in the range of $ 0.185 to $ 3.16 during the past year

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
MYSZMy Size Inc	$ 4.2001 (211.12%)	120.01M
NVNINVNI Group Ltd	$ 8.26 (209.36%)	76.64M
TPICTPI Composites Inc	$ 2.45 (100.82%)	33.95M
ICGIntchains Group Ltd	$ 8.77 (88.60%)	527.61k
HSDTHelius Medical Technologies Inc	$ 0.884851 (84.34%)	120.4M
CYNCYNGN Inc	$ 0.4603 (-71.41%)	27.5M
MTEMMolecular Templates Inc	$ 0.1502 (-57.09%)	8.63M
PRFXPainReform Ltd	$ 5.15 (-53.85%)	2.84M
GALTGalectin Therapeutics Inc	$ 1.03 (-48.50%)	8.58M
BCABBioAtla Inc	$ 0.6923 (-41.82%)	5.96M
EDBLEdible Garden AG Inc	$ 0.24 (65.06%)	354.32M
APTOAptose Biosciences Inc	$ 0.28 (64.51%)	305.1M
TNXPTonix Pharmaceuticals Holding Corporation	$ 0.606999 (6.49%)	292.16M
NVDANVIDIA Corporation	$ 134.70 (3.08%)	287.21M
PLTRPalantir Technologies Inc	$ 80.55 (8.54%)	277.63M